

Winter 1-1-2016

Low-Dose Aronia melanocarpa Concentrate Attenuates Paraquat-Induced Neurotoxicity.

Adam J. Case
University of Nebraska Medical Center, adam.case@unmc.edu

D Agraz
University of Nebraska Medical Center

Iman M. Ahmad
University of Nebraska Medical Center, iman.ahmad@unmc.edu

Matthew C. Zimmerman
University of Nebraska Medical Center, mczimmerman@unmc.edu

Tell us how you used this information in this [short survey](#).

Follow this and additional works at: https://digitalcommons.unmc.edu/com_cell_articles



Part of the [Cellular and Molecular Physiology Commons](#), [Medical Physiology Commons](#), and the [Systems and Integrative Physiology Commons](#)

Recommended Citation

Case, Adam J.; Agraz, D; Ahmad, Iman M.; and Zimmerman, Matthew C., "Low-Dose Aronia melanocarpa Concentrate Attenuates Paraquat-Induced Neurotoxicity." (2016). *Journal Articles: Cellular & Integrative Physiology*. 20.

https://digitalcommons.unmc.edu/com_cell_articles/20

This Article is brought to you for free and open access by the Cellular & Integrative Physiology at DigitalCommons@UNMC. It has been accepted for inclusion in Journal Articles: Cellular & Integrative Physiology by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Research Article

Low-Dose *Aronia melanocarpa* Concentrate Attenuates Paraquat-Induced Neurotoxicity

A. J. Case,¹ D. Agraz,¹ I. M. Ahmad,² and M. C. Zimmerman^{1,3}

¹Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198-5850, USA

²College of Allied Health Professions, University of Nebraska Medical Center, Omaha, NE 68198, USA

³Redox Biology Center, University of Nebraska Lincoln, Lincoln, NE 68588, USA

Correspondence should be addressed to M. C. Zimmerman; mczimmerman@unmc.edu

Received 25 June 2015; Revised 26 August 2015; Accepted 30 August 2015

Academic Editor: Wei Chen

Copyright © 2016 A. J. Case et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Herbicides containing paraquat may contribute to the pathogenesis of neurodegenerative disorders such as Parkinson's disease. Paraquat induces reactive oxygen species-mediated apoptosis in neurons, which is a primary mechanism behind its toxicity. We sought to test the effectiveness of a commercially available polyphenol-rich *Aronia melanocarpa* (aronia berry) concentrate in the amelioration of paraquat-induced neurotoxicity. Considering the abundance of antioxidants in aronia berries, we hypothesized that aronia berry concentrate attenuates the paraquat-induced increase in reactive oxygen species and protects against paraquat-mediated neuronal cell death. Using a neuronal cell culture model, we observed that low doses of aronia berry concentrate protected against paraquat-mediated neurotoxicity. Additionally, low doses of the concentrate attenuated the paraquat-induced increase in superoxide, hydrogen peroxide, and oxidized glutathione levels. Interestingly, high doses of aronia berry concentrate increased neuronal superoxide levels independent of paraquat, while at the same time decreasing hydrogen peroxide. Moreover, high-dose aronia berry concentrate potentiated paraquat-induced superoxide production and neuronal cell death. In summary, aronia berry concentrate at low doses restores the homeostatic redox environment of neurons treated with paraquat, while high doses exacerbate the imbalance leading to further cell death. Our findings support that moderate levels of aronia berry concentrate may prevent reactive oxygen species-mediated neurotoxicity.

1. Introduction

Neurodegeneration is a hallmark of numerous neurological disorders such as age-related dementia, Alzheimer's disease, and Parkinson's disease [1]. While several etiologies have been identified leading to the loss of neurons, one possible contributing factor is contact with environmental toxins [2]. A major source of these poisons in rural farming areas is insecticides and herbicides, and exposure to these has been suggested as a major risk factor for neurological diseases such as Parkinson's disease [3, 4]. One commonly used compound in herbicides is paraquat (PQ), and extensive research has demonstrated a direct link between neurotoxicity and PQ contact [5–7]. PQ is a known redox cycling agent that impacts complex I activity of the mitochondria, increases superoxide ($O_2^{\bullet-}$) production, and decreases endogenous antioxidant capacity leading to increased neurotoxicity through

apoptosis [8, 9]. Several studies have examined the effects of single antioxidant supplementation in the amelioration of PQ-induced neurotoxicity [10–12], but to date it remains unclear how combinations of small molecule antioxidants gained through dietary or nutritional means affect this toxin-mediated neuron loss.

Aronia melanocarpa, also known as black chokeberries or simply aronia berries, are small, dark, cherry-like berries belonging to the plant family Rosaceae [13]. Aronia berries are native to Eastern Europe and the Eastern United States but have recently become cultivated in large quantities by Midwest farmers. The berries have garnered much attention by the general public due to their significantly high quantity of polyphenols, in particular anthocyanins and flavonoids, which are estimated at 2–3 times greater amounts than in comparable berries [14, 15]. Polyphenols, such as resveratrol and quercetin, have been shown to possess significant

antioxidant properties by both directly scavenging reactive oxygen species (ROS) and inducing cellular antioxidant systems to help combat oxidative environments [15]. Aronia berries are no exception, and a widespread literature exists examining the potential beneficial effect of aronia berries on diseases including hypercholesterolemia, cancer, diabetes, and inflammation [16–19]. However, the vast majority of these studies only examine enriched extracts of the polyphenols from aronia berries and not the effects of the whole berry or berry concentrate in the disease models. Moreover, a dearth of studies exists examining the potential beneficial effects of aronia berries on diseases affecting the nervous system.

Herein, we tested the hypothesis that polyphenolic-rich aronia berry concentrate (AB) has antioxidant protective effects against ROS-induced neurotoxicity by PQ. Utilizing a neuronal cell culture model, we indeed demonstrate AB protects against PQ-induced cellular toxicity and an increase in ROS. However, we show that only low doses of AB demonstrate this protective effect, while high doses potentiate the negative effects elicited by PQ. Overall, this work suggests a proper balance of prooxidants and antioxidants are required for normal neuronal homeostasis, and moderate levels of AB shift the balance in favor of neuronal survival following PQ exposure.

2. Materials and Methods

2.1. Cell Culture and Reagents. NG108-15 neuroblastoma cells (ATCC #HB-12317) were cultured and maintained in RPMI 1640 (Gibco #11875-093, Grand Island, NY) supplemented with 10% fetal bovine serum (Atlanta Biologicals #S11150, Lawrenceville, GA) and 1% penicillin/streptomycin (Gibco #15140-122, Grand Island, NY). As per manufacturer's instructions for human consumption, the aronia berry concentrate (Superberries/Mae's Health and Wellness-Westin Foods, Omaha, NE) was diluted to the drinking concentration (1:16 in culture media) prior to making serial working dilutions. Paraquat (Sigma-Aldrich #36541, St. Louis, MO) was diluted in double-distilled water and filter-sterilized prior to use. Cells were plated (200,000 cells/60 mm dish) 24 hours prior to counting or treatment at 0 hours. For AB + PQ experiments, AB was started at 0 hours and PQ was started at 24 hours; pretreatment was performed to examine the protective effects of AB to PQ toxicity. Media were made fresh and changed daily.

2.2. Growth Curves and Apoptosis Assays. For growth curve analyses, cells were washed twice to remove unattached dead cells. Remaining live and attached cells were scrape harvested, isolated by centrifugation, and counted using size exclusion on a Beckman Coulter counter [20]. Apoptotic fraction of live cells was performed on the same cell population using the Alexa Fluor 488 annexin V/Dead Cell Apoptosis Kit (Molecular Probes #V13241, Grand Island, NY) as per manufacturer's instructions [21]. Briefly, freshly isolated cells were incubated with an Alexa Fluor 488-conjugated annexin V antibody as well as propidium iodide (PI). Cells were analyzed on a FACSCalibur flow cytometer (Becton Dickinson, Franklin

Lakes, NJ) at 488 nm excitation and 535 and 610 emission for annexin V and PI, respectively. Apoptotic fraction was considered as cells that were annexin V positive, while remaining are PI negative.

2.3. Superoxide Quantification. Cells were resuspended in serum-free, phenol red-free RPMI 1640 (Gibco #11835-030, Grand Island, NY) with 10 μ M dihydroethidium (DHE; VWR #101447-534, Chicago, IL) for measuring total cellular $O_2^{\cdot-}$ levels or with 10 μ M MitoSOX (Life Technologies #M36008, Grand Island, NY) to measure mitochondrial-specific $O_2^{\cdot-}$ levels and incubated for 30 min at 37°C. Following this, cells were immediately centrifuged at 4°C and resuspended in ice-cold serum-free, phenol red-free media. Cells were analyzed immediately on a LSRII Green Laser flow cytometer (Becton Dickinson, Franklin Lakes, NJ) at 488 nm excitation and 610 nm emission and quantified using FlowJo cytometric analysis software (Tree Star, Ashland, OR) [20].

2.4. Hydrogen Peroxide (H_2O_2) Quantification. Replication-deficient recombinant adenoviruses (Ad5-CMV) encoding either HyPer Cyto (Cytoplasm-targeted HyPer construct; Evrogen #FP941, Moscow, Russia) or HyPer-Mito (Mitochondria-targeted HyPer construct, Evrogen #FP942, Moscow, Russia) were purchased from the University of Iowa Viral Vector Core Facility (Iowa City, IA). After plating, cells were transduced with 100 multiplicity of infection (MOI; transduction efficiency measured at 95.4% \pm 3.2% by flow cytometry with negligible toxicity) of respective virus for 24 hours in serum-free media prior to treatment with AB or PQ. Following treatment, cells were analyzed immediately on a LSRII Green Laser flow cytometer at 488 nm excitation and 509 nm emission and quantified using FlowJo cytometric analysis software [22].

2.5. Western Blotting Analysis. Immunoblotting was performed on whole cell lysates. Samples were separated on 10% denaturing gels, followed by a transfer to nitrocellulose membranes. After blocking in 5% milk in Tris-Buffered Saline and Tween 20, membranes were incubated with primary antibody (copper/zinc superoxide dismutase, CuZnSOD, 1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA; manganese superoxide dismutase, MnSOD, 1:1000 dilution, Upstate Biotech/Millipore, Billerica, MA; catalase, 1:1000 dilution, Abcam, Cambridge, MA; NADPH oxidase 2, Nox2, 1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA; NADPH oxidase 4, Nox4, 1:500 dilution, Novus Biologicals, Littleton, CO; β -actin, 1:1000 dilution, Sigma-Aldrich, St. Louis, MO) overnight at 4°C. Following washout of primary antibody, membranes were incubated with secondary antibody (1:10,000, Thermo Scientific, Rockford, IL) for 1 hour at room temperature. After addition of chemiluminescence substrate (SuperSignal West Femto, Thermo Scientific, Rockford, IL), images were acquired on a UVP Bioimaging System (UVP LLC, Upland, CA) [23].

2.6. Antioxidant Activity Gels. Activity gels were run utilizing whole cell lysates. Samples were separated on 12% nondenaturing gels with ammonium persulfate used as

the polymerization catalyst in the running gel and riboflavin-light in the stacking gel. Gels were prerun for one hour at 4°C prior to sample loading. For superoxide dismutase activity, the gel was stained in a solution containing 2.43 mM nitroblue tetrazolium, 28 mM tetramethylethylenediamine, and 25 μM riboflavin-5'-phosphate for 20 minutes at room temperature protected from light. Following this incubation, the gel was rinsed thrice with double-distilled water and allowed to expose under fluorescent light. For catalase activity, the gel was first allowed to incubate in a 0.003% H₂O₂ solution for 10 minutes prior to staining with 2% ferric chloride and 2% potassium ferricyanide. Gel images were obtained by scanning using a Brother MFC-8870DW scanner [24].

2.7. Glutathione Assay. Oxidized (GSSG) as well as reduced (GSH) glutathione was measured using the GSSG/GSH Quantification kit (Dojindo Molecular Technologies #G257-10, Rockville, MD) as per manufacturer's instructions. Briefly, the assay is based on the glutathione dependent reduction of 5,5'-dithiobis-2-nitrobenzoic acid to 5-mercapto-2-nitrobenzoic acid (λ_{\max} : 415 nm). Absorbance was measured at 415 nm using a SpectraMax M5 multimode plate reader (Molecular Devices, Sunnyvale, CA) [25].

2.8. Statistics. Data are presented as mean ± standard error of the mean (SEM). For two group comparisons, Student's *t*-test was used. For multiple group comparisons, one-way ANOVA followed by Newman-Keuls posttest was used. GraphPad Prism 5.0 statistical and graphing software was used for all analyses. Differences were considered significant at *p* < 0.05.

3. Results

3.1. AB Protects Neurons from PQ-Induced Cell Death. PQ is a well-established neurotoxin known to induce neuron cell death by ROS-mediated apoptosis [26]. To identify an appropriate dose of PQ required to induce neurotoxicity in our neuronal cell culture model, we performed growth curves in the presence of increasing amounts of PQ and identified the IC₅₀ of PQ to be approximately 50 μM (Figure 1(a)). Additionally, to understand if AB alone had any effects on cellular viability we exposed cells to increasing concentrations of AB in 10-fold serial dilutions (Figure 1(b)). Only the highest dose tested (i.e., 1:10 AB) demonstrated significant toxicity to the cells and thus was not used in further studies. Last, to identify if AB had any effect on attenuating PQ-induced neurotoxicity, we treated cells with various dilutions of AB with 50 μM PQ (Figure 1(c), left panel). Interestingly, only the lowest concentrations of AB (i.e., 1:1000 and 1:10000) demonstrated significant rescuing effects on the PQ-treated cells. In contrast, the highest concentration of AB (i.e., 1:100) potentiated the PQ-induced cell death at 72 hours. Furthermore, low doses of AB decreased, while high doses of AB exacerbated the apoptotic fraction of PQ-treated NG108-15 cells (Figure 1(c), right panel). Taken together, these data suggest that lower doses of AB have protective effects against PQ-induced neurotoxicity.

3.2. PQ-Induced Increase in O₂^{•-} Levels Is Attenuated by Low-Dose AB. The primary and direct ROS generated by PQ is O₂^{•-}. We first measured total cellular O₂^{•-} utilizing the O₂^{•-}-sensitive probe DHE (Figure 2(a)). As expected, PQ alone increased DHE oxidation roughly 2-fold. Interestingly, low-dose AB significantly attenuated the PQ-induced increase in O₂^{•-} levels, while high-dose AB exacerbated this response. In addition, high-dose AB alone significantly increased DHE oxidation in the absence of PQ. Next, because PQ is known to play a role in the direct generation of mitochondrial-localized O₂^{•-}, we measured mitochondrial-specific O₂^{•-} levels using MitoSOX Red (Figure 2(b)). Similar to what we observed with total cellular O₂^{•-} levels, PQ alone also significantly increased mitochondrial O₂^{•-} levels. Low-dose AB moderately decreased these levels, but these differences were not statistically significant. Additionally, high-dose AB alone increased mitochondrial O₂^{•-} levels and once again intensified PQ-induced mitochondrial O₂^{•-}. In summary, these data suggest that low, but not high, doses of AB may have antioxidant effects that reduce the PQ-induced increase in neuronal O₂^{•-} levels.

3.3. AB Alters Steady-State Cellular H₂O₂ Levels. O₂^{•-} is a short lived species that is spontaneously and enzymatically (by superoxide dismutases) converted to H₂O₂ [27]. To assess intracellular H₂O₂ levels, we utilized fluorescent proteins that increase in fluorescence when oxidized specifically by H₂O₂ (i.e., HyPer) [22]. First, using a cytoplasm-targeted HyPer (HyPer Cyto) we observed a dose-dependent decrease in cytoplasmic H₂O₂ levels with increased concentration of AB alone (Figure 3(a)). PQ treatment led to a small but significant increase in cytoplasmic H₂O₂ levels, and this response was attenuated with increasing doses of AB. Neither PQ nor AB had any effect on mitochondrial-localized H₂O₂ levels as measured by the mitochondrial-targeted HyPer construct (Hyper Mito; Figure 3(b)). These data suggest that AB has potent H₂O₂ scavenging effects under both normal, nonoxidative stress and PQ-induced oxidative stress conditions.

3.4. AB Has a Minimal Effect on Prooxidant and Antioxidant Enzyme and Activity Levels. The decrease in ROS observed by the addition of AB may be due to direct scavenging of ROS or by the alteration of endogenous antioxidant or prooxidant enzyme systems. First, we performed western blot analyses on whole cell lysates and observed no significant changes in the protein levels of cytoplasmic CuZnSOD, mitochondrial MnSOD, or the peroxisomal H₂O₂ removing enzyme catalase (Figure 4(a)). Because polyphenolic compounds like those found in AB have been shown to activate the sirtuin class of enzymes [28], which may alter the activity of endogenous antioxidant enzymes [29], we further examined antioxidant enzyme activities for both SOD and catalase and observed no significant differences in any treatment group (Figure 4(b)). In addition to exploring endogenous antioxidant systems, we also investigated the prooxidant NADPH oxidase (Nox) family of enzymes, which contribute to the production and steady-state levels of cellular O₂^{•-} and H₂O₂ levels. Examining the catalytic subunits of the two major Nox




FIGURE 1: AB attenuates PQ-induced neurotoxicity. NG108-15 cells were treated with various doses of PQ, AB, or AB + PQ for 72 hours. (a) Growth curve of NG108-15 cells with increasing doses of PQ. IC_{50} of PQ calculated at approximately 50 μM . $N = 6$. (b) Growth curve of NG108-15 cells with increasing doses of AB. 1:10 AB demonstrated significant toxicity and thus was not used in further studies. $N = 6$. (c) Left panel, growth curve of NG108-15 cells with 50 μM of PQ along with various doses of AB. AB was added at 0 hours, while PQ was added at 24 hours after plating. $N = 6$. Right panel, analysis of apoptotic NG108-15 cells with 50 μM of PQ along with various doses of AB. Apoptotic fraction was defined as annexin V positive and propidium iodide (PI) negative. $N = 4$. * $p < 0.05$ versus No PQ or AB; $\Psi p < 0.05$ versus PQ-No AB.

enzymes found in neurons (i.e. Nox2 and Nox4) we observed a substantial reduction in the amount of immunoreactivity for Nox2 with high-dose AB independent of PQ treatment (Figure 4(a)), but no changes were observed with lower doses. Taken together, while high-dose AB appears to have an effect on Nox2 levels, overall, AB does not appear to have a significant impact on the endogenous antioxidant or prooxidant enzyme systems in our neuronal cell culture model.

3.5. PQ-Induced Oxidized Glutathione Is Significantly Reduced with Low-Dose AB.

In addition to antioxidant enzyme

systems, the cell is home to numerous small molecule antioxidant systems. The most abundant small molecule antioxidant system in the cell is glutathione, which may be cycled between a reduced and oxidized state depending on the redox environment of the cell and has shown incredible importance in attenuating ROS-induced neurotoxicity [8, 30]. When examining GSH in our neuronal cell culture model, we observed no significant changes in any treatment group (Figure 5(a)). In contrast, when measuring GSSG we observed that PQ alone increased GSSG roughly 4-fold compared to control neurons. Moreover, low-dose AB




FIGURE 2: Low-dose AB decreases PQ-induced increase in $O_2^{\bullet-}$ levels. NG108-15 cells were treated with 50 μ M PQ with various doses of AB. AB was added 24 hours prior to PQ; cells were analyzed 48 hours after PQ administration. (a) Total cellular $O_2^{\bullet-}$ levels measured by dihydroethidium (DHE) oxidation and flow cytometry. $N = 4$. (b) Mitochondrial-specific $O_2^{\bullet-}$ levels measured by MitoSOX oxidation and flow cytometry. MFI = mean fluorescence intensity. $N = 4$. * $p < 0.05$ versus No AB; † $p < 0.05$ versus PQ-No AB.




FIGURE 3: AB decreases cellular H_2O_2 in a dose-dependent fashion. NG108-15 cells were treated with 50 μ M PQ with various doses of AB. AB was added 24 hours prior to PQ; cells were analyzed 48 hours after PQ administration. (a) Cytoplasmic H_2O_2 levels measured by a cytoplasmic-targeted H_2O_2 -sensitive fluorescent protein (HyPer Cyto). $N = 4$. (b) Mitochondrial H_2O_2 levels measured by a mitochondria-targeted H_2O_2 -sensitive fluorescent protein (HyPer Mito). MFI = mean fluorescence intensity. $N = 4$. * $p < 0.05$ versus No AB; † $p < 0.05$ versus PQ-No AB.

attenuated the PQ-elevated GSSG levels back to control levels, while high-dose AB had no significant change on GSSG levels in PQ-treated cells (Figure 5(b)). Overall, these findings support our $O_2^{\bullet-}$ and H_2O_2 data (Figures 2 and 3) and together strongly suggest that low-dose AB decreases levels of ROS, attenuates oxidative stress, and inhibits neurotoxicity following PQ exposure.

4. Discussion

Of the neurodegenerative diseases, Parkinson's disease is highly associated with oxidative stress induced by environmental factors such as herbicide (i.e., PQ) exposure [31]. While the exact cause of Parkinson's disease remains elusive, numerous studies have elucidated excess ROS production to




FIGURE 4: High-dose AB decreases Nox2 expression but does not affect other cellular antioxidant or prooxidant enzyme systems. NG108-15 cells were treated with $50 \mu\text{M}$ PQ with various doses of AB. AB was added 24 hours prior to PQ; cells were analyzed 48 hours after PQ administration. (a) Western blot analysis of the major neuronal prooxidant enzymes NADPH oxidases 2 and 4 (Nox2 and Nox4) and antioxidant enzymes catalase, manganese superoxide dismutase (MnSOD), and copper/zinc superoxide dismutase (CuZnSOD). (b) In-gel activity assay for catalase and SOD demonstrating no change with any treatment course. Images are representative of 4 separate experiments; with the exception of Nox2, no significant changes were observed upon quantification.




FIGURE 5: Low-dose AB rescues neurons from PQ-mediated increases in oxidized glutathione (GSSG). NG108-15 cells were treated with $50 \mu\text{M}$ PQ with various doses of AB. AB was added 24 hours prior to PQ; cells were analyzed 48 hours after PQ administration. (a) Relative levels of reduced glutathione (GSH). $N = 3$. (b) Relative levels of oxidized glutathione (GSSG). $N = 3$. * $p < 0.05$ versus No AB; $\Psi p < 0.05$ versus PQ-No AB.

be a potential mechanism in the loss of critical dopaminergic neurons in the substantia nigra in the brain [32]. A primary source of intraneuronal ROS, more specifically $\text{O}_2^{\bullet-}$, implicated to be involved in the disease is complex I of mitochondria [33]. Complex I inhibitors (which are also found in pesticides and herbicides) such as rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) create a backup of electrons in the mitochondrial respiratory chain, which further leak onto molecular oxygen generating $\text{O}_2^{\bullet-}$

and induce oxidative stress [34]. Interestingly, PQ possesses a similar structure to MPTP and has also been demonstrated to interact with complex I to generate reactive radical species [35]. Herein, we confirm these findings by demonstrating that mitochondrial $\text{O}_2^{\bullet-}$ is indeed increased in NG108-15 cells treated with PQ. Intriguingly, we observed no change in mitochondrial H_2O_2 levels, which suggests a predominantly 1 electron transfer to generate primarily $\text{O}_2^{\bullet-}$. Moreover, low doses of AB were able to significantly attenuate this

increase in mitochondrial oxidative stress, which translated to a more reducing cellular environment as evidenced by lower DHE oxidation as well as decreased levels of oxidized glutathione. In contrast, high doses of AB could not rescue the PQ-induced oxidative stress and exacerbated some of the effects. These findings warrant examination into the specific components of the AB concentrate to elucidate potential molecules that could exacerbate redox cycling reactions in a dose-dependent manner.

There are currently limited medical therapies for the treatment of neurodegenerative diseases. On the contrary, a breadth of evidence exists suggesting dietary intake of polyphenols may have beneficial effects in counteracting neurological disorders. For example, consumption of red wine, which is known to possess high levels of polyphenols, may reduce the incidence of neurological disorders [36, 37]. Other studies have demonstrated intake of polyphenol-rich foods may preserve cognitive function, delay the onset, or even reduce the risk of neurodegenerative diseases like age-related dementia or Alzheimer's disease [38–40]. However, it remains controversial if the beneficial effects of polyphenol-rich diets are actually acting in the brain, as it is not clear if polyphenols cross the blood brain barrier [41]. Polyphenols have been reported to be poorly absorbed by the intestines, rapidly excreted, and exist in low concentrations in systemic circulation [42, 43], which further argues for a potential limited role in the brain. In contrast, several investigations have concluded that low concentrations of polyphenols do in fact cross the blood brain barrier under both experimental *in situ* conditions and after *in vivo* dietary consumption of polyphenol-rich foods [44–47]. In the present study, we identified that only low concentrations of AB provided a protective role against ROS-induced neuron cell death caused by PQ. With the understanding that only small amounts of polyphenols may reach the brain after dietary consumption of polyphenol-rich foods, our data support a beneficial and antioxidant effect of these molecules in low concentrations and the possible protection against neuron cell death.

The use of antioxidants as therapeutics is controversial due to an extensive list of failed clinical trials in an array of diseases. Based on this, it is easy to conclude that antioxidants are not sufficient in ameliorating disease, but numerous variables must be taken into account when assessing the efficacy of these trials. The first variable to consider is dosage. It is commonly presumed in medicine that if a positive dose response to a drug is achieved at low concentrations then high concentrations will produce an even more favorable outcome, but this is not always found to be true. For example, in 2002 a phase II, double blind, randomized, and placebo controlled clinical trial was performed on the potential effectiveness of coenzyme Q₁₀ in slowing the progression of Parkinson's disease [48]. A negative correlation was observed with increasing dose of coenzyme Q₁₀ (ranging from 300 to 1200 mg/day) and progression of the disease, which thus prompted researchers to investigate even higher doses of coenzyme Q₁₀ in Parkinson's disease. In 2007, another phase II, double blind, randomized, and placebo controlled study was performed utilizing doses of coenzyme Q₁₀ ranging from 2400 to 4000 mg/day and found no significant improvement

with any dose on the diminution of progression of Parkinson's disease [49]. The conclusion drawn from this study was that coenzyme Q₁₀ provided no benefit over placebo in Parkinson's disease due to the fact that high doses could not replicate what was seen in the lower dose clinical trial. Another example of dosage discrepancies involves the use of vitamin E for therapy in Alzheimer's or Parkinson's disease patients. Three separate clinical trials utilizing vitamin E supplements (ranging from 800 to 2000 IU/day) found no significant impact or even worsening of the severity of Alzheimer's or Parkinson's disease progression [50–52]. However, three separate studies utilizing vitamin E administration through means of dietary intake (ranging from 5 to 15 mg/day in foods naturally containing higher levels of vitamin E) showed positive benefits in slowing the progression of both diseases [53–55]. Similar to what was observed with coenzyme Q₁₀, it appears that lower doses (and possibly vehicle of administration) are possibly more efficacious than higher doses when examining the effects of antioxidants. In our study presented here, we observe a similar phenomenon where only low-dose AB ameliorated PQ-induced neurotoxicity, while higher doses exacerbated the phenotype. This nonlinear regression between antioxidant dosage and disease outcome may explain the subjective failure of antioxidant clinical trials and warrants further investigation into the potential mechanisms leading to the nonmonotonic response.

Another significant variable in the outcome of antioxidant therapy is the timing of administration. The majority of clinical trials focus on the treatment of patients that have already been diagnosed with a major disease, and as such assessing the preventative capabilities of antioxidants is already past due. Conversely, numerous retrospective analyses have examined the potential for dietary intake of antioxidants in altering the risk of developing neurodegenerative disorders like Alzheimer's disease. For example, it has been shown that diets rich in fruits and vegetables reduce cognitive decline and the risk for Alzheimer's disease later in life [56, 57]. Additionally, in the aforementioned Rotterdam study it was observed that intake of vitamin E in the form of food (not supplements) also reduced the incidence of dementia [54]. These studies suggest that antioxidants serve as preventative measures as opposed to reactive measures against neurological disorders. Herein, we present evidence that supports this hypothesis as we show pretreatment of neurons with AB for 24 hours prior to PQ administration protects neurons from ROS-induced cell death. Performing the converse experiment in which AB was administered at the same time or 24 hours after PQ treatment did not produce any observable beneficial response (data not shown). Taken together, antioxidant supplementation through dietary intake appears to play a greater role in the prevention of neurological diseases as opposed to their treatment.

The last major variable to consider when assessing the efficacy of antioxidants in the treatment of diseases is the specific ROS that is being targeted. ROS are often considered a homogenous group of substances that are harmful to the cell, but this view overlooks the vast complexity of the redox environment. ROS are diverse with some being free radicals, possessing charges, or participating in one or two

electron oxidation/reduction reactions depending on the structure of the specific species [58]. Additionally, not all ROS cause “oxidative stress,” which is defined as irreversible damage to cellular components, but many ROS participate in controlled, regulated, and reversible modifications to cellular constituents that lead to redox-mediated signaling pathways [59]. For example, H_2O_2 oxidizes reduced cysteines in proteins creating reversible adducts that may alter the shape and function of a protein, thus making the protein redox responsive [60]. In contrast, $O_2^{\bullet-}$ is a poor oxidant but reacts readily with iron-sulfur cluster containing enzymes reversibly affecting their activity and contributing to redox-mediated cellular signaling [61]. With the understanding that ROS-mediated reactions are unique and diverse, it becomes clear that the use of a generalized antioxidant that may scavenge several ROS at once (or potentially a ROS that is not highly relevant in the disease state) may not prove to be efficacious or even deleterious. In our data set, we demonstrate that the primary ROS produced by PQ is $O_2^{\bullet-}$, and this has been shown by others as well [26]. Low doses of AB demonstrated the ability to significantly attenuate PQ-induced $O_2^{\bullet-}$ in neurons, yet, high doses potentiated the production. Moreover, high dose of AB appeared to significantly reduce the amount of steady-state H_2O_2 in neurons even in the absence of PQ suggesting that high dosage of antioxidants altered normal redox signaling within the cells or even created a reductive stress upon the cells [62]. In summary, it appears that low, but not high, dose of AB restores the homeostatic redox environment and decreases cellular death caused by the PQ-induced $O_2^{\bullet-}$ -mediated oxidative stress.

Next, we observed an interesting phenomenon that Nox2 protein was virtually absent in neurons treated with high doses of AB (independent of PQ treatment). Polyphenols have been demonstrated to attenuate Nox activity in various models, but their role in regulating actual protein levels is unclear [63–65]. Our data suggest that AB may be interfering with the normal expression of Nox2, but it is unclear at this time if this occurs at the transcriptional, posttranscriptional, translational, or posttranslational level. Furthermore, the Nox2 catalytic subunit of the Nox complex is also known as gp91phox due to the fact that the 55 kDa protein becomes heavily glycosylated causing it to run on a western blot at approximately 91 kDa [66]. Polyphenols have been shown to interfere with and reduce the amount of advanced end glycation products observed in several disease states [67–69], which raises the question if these small molecules also play a role in modifying normal cellular glycosylation of proteins. Our data suggest AB plays a significant role in the downregulation of Nox2, and further investigation is warranted into the mechanism of this process.

Finally, our study does possess some potential limitations. First, due to proprietary reasons we are limited in the understanding of the exact constituents and concentrations of the commercially available AB concentrate. Additionally, while the dilutions we utilized did produce favorable outcomes, further biodistribution studies are needed to understand if the optimal concentrations we observed translate *in vivo*. Next, our use of a neuronal cell line may not perfectly mimic the effects on primary neurons. However, NG108-15 cells

divide and grow in a highly differentiated manner, which increases their likelihood to react like primary neurons in an *in vitro* setting. Lastly, treatment of neuronal cells *in vitro* with AB does not take into account *in vivo* variables such as absorption and biotransformation that may alter the AB components and exposure to neurons in a living system. Upon consumption, polyphenols may be oxidized by liver enzymes and the digestive microbiota, which could ultimately change the structure and function of these molecules once they have reached a target organ. While our current studies do not address the potential alterations digestion may have on the AB, we believe the data presented herein show significant preliminary promise for AB in the amelioration of ROS-induced neurotoxicity. With these promising results, we are currently investigating the ability of AB to attenuate neurological dysfunction *in vivo* utilizing various animal models of neurodegeneration. These models will allow for a deeper understanding regarding AB bioavailability to neurons of the central nervous system, and if concentrations are able to reach levels necessary for the attenuation of oxidative stress-mediated neurological disease.

Abbreviations

PQ:	Paraquat
$O_2^{\bullet-}$:	Superoxide
ROS:	Reactive oxygen species
AB:	Aronia berry concentrate
DHE:	Dihydroethidium
H_2O_2 :	Hydrogen peroxide
CuZnSOD:	Copper/zinc superoxide dismutase
MnSOD:	Manganese superoxide dismutase
GSH:	Reduced glutathione
GSSG:	Oxidized glutathione
Nox:	NADPH oxidase.

Conflict of Interests

No conflict of interests exists for all authors.

Authors' Contribution

A. J. Case, D. Agraz, and M. C. Zimmerman designed research; A. J. Case, D. Agraz, and I. M. Ahmad conducted research; A. J. Case, D. Agraz, and I. M. Ahmad analyzed data; A. J. Case and M. C. Zimmerman wrote the paper; M. C. Zimmerman had primary responsibility for final content. All authors read and approved the final paper.

Acknowledgments




The authors thank Superberries/Mae's Health and Wellness LLC/Westin Foods for providing the aronia berry concentrate used for these studies. This work was supported by institutional and departmental funds awarded to M. C. Zimmerman.

References

- [1] A. Xie, J. Gao, L. Xu, and D. Meng, "Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease," *BioMed Research International*, vol. 2014, Article ID 648740, 8 pages, 2014.
- [2] M. T. Baltazar, R. J. Dinis-Oliveira, M. de Lourdes Bastos, A. M. Tsatsakis, J. A. Duarte, and F. Carvalho, "Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases—a mechanistic approach," *Toxicology Letters*, vol. 230, no. 2, pp. 85–103, 2014.
- [3] C. Freire and S. Koifman, "Pesticide exposure and Parkinson's disease: epidemiological evidence of association," *NeuroToxicology*, vol. 33, no. 5, pp. 947–971, 2012.
- [4] C. M. Tanner, F. Kame, G. W. Ross et al., "Rotenone, paraquat, and Parkinson's disease," *Environmental Health Perspectives*, vol. 119, no. 6, pp. 866–872, 2011.
- [5] F. Wang, R. Franco, M. Skotak, G. Hu, and N. Chandra, "Mechanical stretch exacerbates the cell death in SH-SY5Y cells exposed to paraquat: mitochondrial dysfunction and oxidative stress," *NeuroToxicology*, vol. 41, pp. 54–63, 2014.
- [6] B. Thrash, S. Uthayathas, S. S. Karuppagounder, V. Suppiramianiam, and M. Dhanasekaran, "Paraquat and maneb induced neurotoxicity," *Proceedings of the Western Pharmacology Society*, vol. 50, pp. 31–42, 2007.
- [7] R. Franco, S. Li, H. Rodriguez-Rocha, M. Burns, and M. I. Panayiotidis, "Molecular mechanisms of pesticide-induced neurotoxicity: relevance to Parkinson's disease," *Chemico-Biological Interactions*, vol. 188, no. 2, pp. 289–300, 2010.
- [8] W. Yang and E. Tiffany-Castiglioni, "The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis," *Journal of Toxicology and Environmental Health Part A*, vol. 68, no. 22, pp. 1939–1961, 2005.
- [9] W. Yang and E. Tiffany-Castiglioni, "Paraquat-induced apoptosis in human neuroblastoma SH-SY5Y cells: involvement of p53 and mitochondria," *Journal of Toxicology and Environmental Health Part A*, vol. 71, no. 4, pp. 289–299, 2008.
- [10] S. Medina-Leendertz, M. Paz, M. Mora et al., "Longterm melatonin administration alleviates paraquat mediated oxidative stress in *Drosophila melanogaster*," *Investigacion Clinica*, vol. 55, pp. 352–364, 2014.
- [11] I. Ahmad, S. Shukla, A. Kumar et al., "Biochemical and molecular mechanisms of *N*-acetyl cysteine and silymarin-mediated protection against maneb- and paraquat-induced hepatotoxicity in rats," *Chemico-Biological Interactions*, vol. 201, no. 1–3, pp. 9–18, 2013.
- [12] Z. Wang, Y. Xiao, W. Chen, K. Tang, and L. Zhang, "Increased vitamin C content accompanied by an enhanced recycling pathway confers oxidative stress tolerance in *Arabidopsis*," *Journal of Integrative Plant Biology*, vol. 52, no. 4, pp. 400–409, 2010.
- [13] S. E. Kulling and H. M. Rawel, "Chokeberry (*Aronia melanocarpa*)—a review on the characteristic components and potential health effects," *Planta Medica*, vol. 74, no. 13, pp. 1625–1634, 2008.
- [14] X. Wu, L. Gu, R. L. Prior, and S. McKay, "Characterization of anthocyanins and proanthocyanidins in some cultivars of *Ribes*, *Aronia*, and *Sambucus* and their antioxidant capacity," *Journal of Agricultural and Food Chemistry*, vol. 52, no. 26, pp. 7846–7856, 2004.
- [15] X. Wu, G. R. Beecher, J. M. Holden, D. B. Haytowitz, S. E. Gebhardt, and R. L. Prior, "Concentrations of anthocyanins in common foods in the United States and estimation of normal consumption," *Journal of Agricultural and Food Chemistry*, vol. 54, no. 11, pp. 4069–4075, 2006.
- [16] D. Rugină, Z. Sconța, L. Leopold, A. Pinte, A. Bunea, and C. Socaciu, "Antioxidant activities of chokeberry extracts and the cytotoxic action of their anthocyanin fraction on hela human cervical tumor cells," *Journal of Medicinal Food*, vol. 15, no. 8, pp. 700–706, 2012.
- [17] B. Kim, C. S. Ku, T. X. Pham et al., "Aronia melanocarpa (chokeberry) polyphenol-rich extract improves antioxidant function and reduces total plasma cholesterol in apolipoprotein E knockout mice," *Nutrition Research*, vol. 33, no. 5, pp. 406–413, 2013.
- [18] B. Qin and R. A. Anderson, "An extract of chokeberry attenuates weight gain and modulates insulin, adipogenic and inflammatory signalling pathways in epididymal adipose tissue of rats fed a fructose-rich diet," *The British Journal of Nutrition*, vol. 108, no. 4, pp. 581–587, 2012.
- [19] K. Ohgami, I. Ilieva, K. Shiratori et al., "Anti-inflammatory effects of aronia extract on rat endotoxin-induced uveitis," *Investigative Ophthalmology & Visual Science*, vol. 46, no. 1, pp. 275–281, 2005.
- [20] A. J. Case and M. C. Zimmerman, "Redox-regulated suppression of splenic T-lymphocyte activation in a model of sympathoexcitation," *Hypertension*, vol. 65, no. 4, pp. 916–923, 2015.
- [21] A. J. Case, J. L. McGill, L. T. Tygrett et al., "Elevated mitochondrial superoxide disrupts normal T cell development, impairing adaptive immune responses to an influenza challenge," *Free Radical Biology and Medicine*, vol. 50, no. 3, pp. 448–458, 2011.
- [22] V. V. Belousov, A. F. Fradkov, K. A. Lukyanov et al., "Genetically encoded fluorescent indicator for intracellular hydrogen peroxide," *Nature Methods*, vol. 3, no. 4, pp. 281–286, 2006.
- [23] A. J. Case, S. Li, U. Basu, J. Tian, and M. C. Zimmerman, "Mitochondrial-localized NADPH oxidase 4 is a source of superoxide in angiotensin II-stimulated neurons," *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 305, no. 1, pp. H19–H28, 2013.
- [24] S. Li, A. J. Case, R.-F. Yang, H. D. Schultz, and M. C. Zimmerman, "Over-expressed copper/zinc superoxide dismutase localizes to mitochondria in neurons inhibiting the angiotensin II-mediated increase in mitochondrial superoxide," *Redox Biology*, vol. 2, no. 1, pp. 8–14, 2013.
- [25] I. M. Ahmad, M. Y. Abdalla, N. Aykin-Burns et al., "2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress," *Free Radical Biology and Medicine*, vol. 44, no. 5, pp. 826–834, 2008.
- [26] J. S. Bus and J. E. Gibson, "Paraquat: model for oxidant-initiated toxicity," *Environmental Health Perspectives*, vol. 55, pp. 37–46, 1984.
- [27] I. Fridovich, "Superoxide dismutases," *Annual Review of Biochemistry*, vol. 44, pp. 147–159, 1975.
- [28] D. A. Sinclair and L. Guarente, "Small-molecule allosteric activators of sirtuins," *Annual Review of Pharmacology and Toxicology*, vol. 54, pp. 363–380, 2014.
- [29] O. Ozden, S.-H. Park, H.-S. Kim et al., "Acetylation of MnSOD directs enzymatic activity responding to cellular nutrient status or oxidative stress," *Aging*, vol. 3, no. 2, pp. 102–107, 2011.

- [30] J. S. Bains and C. A. Shaw, "Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death," *Brain Research Reviews*, vol. 25, no. 3, pp. 335–358, 1997.
- [31] J. Blesa, I. Trigo-Damas, A. Quiroga-Varela, and V. R. Jackson-Lewis, "Oxidative stress and Parkinson's disease," *Frontiers in Neuroanatomy*, vol. 9, article 91, 2015.
- [32] J. A. Obeso, M. C. Rodriguez-Oroz, C. G. Goetz et al., "Missing pieces in the Parkinson's disease puzzle," *Nature Medicine*, vol. 16, no. 6, pp. 653–661, 2010.
- [33] A. H. Schapira, "Mitochondria in the aetiology and pathogenesis of Parkinson's disease," *The Lancet Neurology*, vol. 7, no. 1, pp. 97–109, 2008.
- [34] J. Blesa and S. Przedborski, "Parkinson's disease: animal models and dopaminergic cell vulnerability," *Frontiers in Neuroanatomy*, vol. 8, article 155, 2014.
- [35] T. Fukushima, K. Yamada, A. Isobe, K. Shiwaku, and Y. Yamane, "Mechanism of cytotoxicity of paraquat. I. NADH oxidation and paraquat radical formation via complex I," *Experimental and Toxicologic Pathology*, vol. 45, no. 5–6, pp. 345–349, 1993.
- [36] J.-M. Orgogozo, J.-F. Dartigues, S. Lafont et al., "Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area," *Revue Neurologique*, vol. 153, no. 3, pp. 185–192, 1997.
- [37] T. Truelsen, D. Thudium, M. Gronbaek, and Copenhagen City Heart Study, "Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study," *Neurology*, vol. 59, pp. 1313–1319, 2002.
- [38] D. Commenges, V. Scotet, S. Renaud, H. Jacqmin-Gadda, P. Barberger-Gateau, and J.-F. Dartigues, "Intake of flavonoids and risk of dementia," *European Journal of Epidemiology*, vol. 16, no. 4, pp. 357–363, 2000.
- [39] L. Letenneur, C. Proust-Lima, A. Le Gouge, J. F. Dartigues, and P. Barberger-Gateau, "Flavonoid intake and cognitive decline over a 10-year period," *American Journal of Epidemiology*, vol. 165, no. 12, pp. 1364–1371, 2007.
- [40] Q. Dai, A. R. Borenstein, Y. Wu, J. C. Jackson, and E. B. Larson, "Fruit and vegetable juices and Alzheimer's disease: the Kame Project," *American Journal of Medicine*, vol. 119, no. 9, pp. 751–759, 2006.
- [41] S. Schaffer and B. Halliwell, "Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations," *Genes & Nutrition*, vol. 7, no. 2, pp. 99–109, 2012.
- [42] B. Halliwell, "Dietary polyphenols: good, bad, or indifferent for your health?" *Cardiovascular Research*, vol. 73, no. 2, pp. 341–347, 2007.
- [43] S. B. Lotito and B. Frei, "Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?" *Free Radical Biology and Medicine*, vol. 41, no. 12, pp. 1727–1746, 2006.
- [44] K. A. Youdim, M. Z. Qaiser, D. J. Begley, C. A. Rice-Evans, and N. J. Abbott, "Flavonoid permeability across an in situ model of the blood-brain barrier," *Free Radical Biology and Medicine*, vol. 36, no. 5, pp. 592–604, 2004.
- [45] S. Passamonti, U. Vrhovsek, A. Vanzo, and F. Mattivi, "Fast access of some grape pigments to the brain," *Journal of Agricultural and Food Chemistry*, vol. 53, no. 18, pp. 7029–7034, 2005.
- [46] W. Kalt, J. B. Blumberg, J. E. McDonald et al., "Identification of anthocyanins in the liver, eye, and brain of blueberry-fed pigs," *Journal of Agricultural and Food Chemistry*, vol. 56, no. 3, pp. 705–712, 2008.
- [47] P. E. Milbury and W. Kalt, "Xenobiotic metabolism and berry flavonoid transport across the blood-brain barrier," *Journal of Agricultural and Food Chemistry*, vol. 58, no. 7, pp. 3950–3956, 2010.
- [48] C. W. Shults, D. Oakes, K. Kieburtz et al., "Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline," *Archives of Neurology*, vol. 59, no. 10, pp. 1541–1550, 2002.
- [49] NINDS NET-PD Investigators, "A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease," *Neurology*, vol. 68, no. 1, pp. 20–28, 2007.
- [50] R. C. Petersen, R. G. Thomas, M. Grundman et al., "Vitamin E and donepezil for the treatment of mild cognitive impairment," *The New England Journal of Medicine*, vol. 352, no. 23, pp. 2379–2388, 2005.
- [51] I. Shoulson, S. Fahn, D. Oakes et al., "Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease," *The New England Journal of Medicine*, vol. 328, no. 3, pp. 176–183, 1993.
- [52] A. Lloret, M.-C. Badía, N. J. Mora, F. V. Pallardó, M.-D. Alonso, and J. Viña, "Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental," *Journal of Alzheimer's Disease*, vol. 17, no. 1, pp. 143–149, 2009.
- [53] M. C. Morris, D. A. Evans, C. C. Tangney et al., "Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change," *The American Journal of Clinical Nutrition*, vol. 81, no. 2, pp. 508–514, 2005.
- [54] E. E. Devore, F. Grodstein, F. J. A. van Rooij et al., "Dietary antioxidants and long-term risk of dementia," *Archives of Neurology*, vol. 67, no. 7, pp. 819–825, 2010.
- [55] M. C. de Rijk, M. M. B. Breteler, J. H. den Breeijen et al., "Dietary antioxidants and Parkinson disease. The Rotterdam Study," *Archives of Neurology*, vol. 54, no. 6, pp. 762–765, 1997.
- [56] J. H. Kang, A. Ascherio, and F. Grodstein, "Fruit and vegetable consumption and cognitive decline in aging women," *Annals of Neurology*, vol. 57, no. 5, pp. 713–720, 2005.
- [57] M. C. Morris, D. A. Evans, C. C. Tangney, J. L. Bienias, and R. S. Wilson, "Associations of vegetable and fruit consumption with age-related cognitive change," *Neurology*, vol. 67, no. 8, pp. 1370–1376, 2006.
- [58] V. I. Lushchak, "Free radicals, reactive oxygen species, oxidative stress and its classification," *Chemico-Biological Interactions*, vol. 224, pp. 164–175, 2014.
- [59] M. Schieber and N. S. Chandel, "ROS function in redox signaling and oxidative stress," *Current Biology*, vol. 24, no. 10, pp. R453–R462, 2014.
- [60] S. G. Rhee, "H₂O₂, a necessary evil for cell signaling," *Science*, vol. 312, no. 5782, pp. 1882–1883, 2006.
- [61] I. Fridovich, "Superoxide anion radical O₂⁻, superoxide dismutases, and related matters," *The Journal of Biological Chemistry*, vol. 272, no. 30, pp. 18515–18517, 1997.
- [62] J. S. Teodoro, A. P. Rolo, and C. M. Palmeira, "The NAD ratio redox paradox: why does too much reductive power cause oxidative stress?" *Toxicology Mechanisms and Methods*, vol. 23, no. 5, pp. 297–302, 2013.
- [63] N. A. Al-Awwadi, C. Araiz, A. Bornet et al., "Extracts enriched in different polyphenolic families normalize increased cardiac NADPH oxidase expression while having differential effects on insulin resistance, hypertension, and cardiac hypertrophy in high-fructose-fed rats," *Journal of Agricultural and Food Chemistry*, vol. 53, no. 1, pp. 151–157, 2005.

- [64] N. Ryszawa, A. Kawczyńska-Drózd, J. Pryjma et al., “Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis,” *Journal of Physiology and Pharmacology*, vol. 57, no. 4, pp. 611–626, 2006.
- [65] L. K. Sarna, N. Wu, S.-Y. Hwang, Y. L. Siow, and O. Karmin, “Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages,” *Canadian Journal of Physiology and Pharmacology*, vol. 88, no. 3, pp. 369–378, 2010.
- [66] F. R. M. Laurindo, T. L. S. Araujo, and T. B. Abrahão, “Nox NADPH oxidases and the endoplasmic reticulum,” *Antioxidants & Redox Signaling*, vol. 20, no. 17, pp. 2755–2775, 2014.
- [67] T. Yunoki, K. Deguchi, Y. Omote et al., “Anti-oxidative nutrient rich diet protects against acute ischemic brain damage in rats,” *Brain Research*, vol. 1587, no. 1, pp. 33–39, 2014.
- [68] I.-M. Liu, T.-F. Tzeng, S.-S. Liou, and C. J. Chang, “*Angelica acutiloba* root alleviates advanced glycation end-product-mediated renal injury in streptozotocin-diabetic rats,” *Journal of Food Science*, vol. 76, no. 7, pp. H165–H174, 2011.
- [69] A. A. Maruf, H. Lip, H. Wong, and P. J. O’Brien, “Protective effects of ferulic acid and related polyphenols against glyoxal- or methylglyoxal-induced cytotoxicity and oxidative stress in isolated rat hepatocytes,” *Chemico-Biological Interactions*, vol. 234, pp. 96–104, 2015.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

